6:06 PM
 | 
Mar 30, 2015
 |  BC Extra  |  Company News

Horizon buying Hyperion for $1.1B

Horizon Pharma plc (NASDAQ:HZNP) will acquire rare disease company Hyperion Therapeutics Inc. (NASDAQ:HPTX) for $46 per share, or $1.1 billion in cash. The price represents an 8% premium to Hyperion's Friday close of $42.74.

Horizon will gain two marketed...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >